The Insider, Phillip Frost Made a Purchase of 153,000 Shares of OPKO Health, Inc. (OPK); Infinity Pharmaceuticals Has 0.62 Sentiment

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Logo

Infinity Pharmaceuticals Inc (INFI) investors sentiment increased to 0.62 in 2017 Q4. It’s up 0.15, from 0.47 in 2017Q3. The ratio is better, as 21 investment professionals opened new and increased equity positions, while 34 reduced and sold their positions in Infinity Pharmaceuticals Inc. The investment professionals in our database now hold: 24.33 million shares, down from 27.30 million shares in 2017Q3. Also, the number of investment professionals holding Infinity Pharmaceuticals Inc in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 11 Reduced: 23 Increased: 9 New Position: 12.

It closed at $3.04 lastly. It is down 60.81% since April 4, 2017 and is downtrending. It has underperformed by 72.36% the S&P500.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, and Mexico. The company has market cap of $1.70 billion. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases. It currently has negative earnings. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform.

Analysts await OPKO Health, Inc. (NASDAQ:OPK) to report earnings on May, 8. They expect $-0.14 EPS, down 133.33% or $0.08 from last year’s $-0.06 per share. After $-0.12 actual EPS reported by OPKO Health, Inc. for the previous quarter, Wall Street now forecasts 16.67% negative EPS growth.

Since January 22, 2018, it had 27 insider buys, and 0 selling transactions for $7.70 million activity. $625,955 worth of OPKO Health, Inc. (NASDAQ:OPK) was bought by FROST PHILLIP MD ET AL on Wednesday, February 21. Logal Adam had bought 2,065 shares worth $7,011. 6,000 shares were bought by Rubin Steven D, worth $19,500 on Wednesday, March 7.

Investors sentiment decreased to 0.84 in Q4 2017. Its down 0.30, from 1.14 in 2017Q3. It worsened, as 32 investors sold OPKO Health, Inc. shares while 60 reduced holdings. 24 funds opened positions while 53 raised stakes. 119.15 million shares or 0.51% less from 119.76 million shares in 2017Q3 were reported. Renaissance Technologies Limited Liability Corp stated it has 159,991 shares or 0% of all its holdings. State Of Alaska Department Of Revenue reported 29,600 shares. Horizon Kinetics Lc reported 78,019 shares. Vantage Investment Advsr Llc invested 0% of its portfolio in OPKO Health, Inc. (NASDAQ:OPK). Coldstream Mngmt invested in 15,000 shares. Williams Jones & Associate Ltd Limited Liability Company holds 0% or 14,800 shares. 29,473 were accumulated by Asset Mngmt Inc. Michigan-based Comerica State Bank has invested 0% in OPKO Health, Inc. (NASDAQ:OPK). Legal And General Group Public Lc owns 209,512 shares. Employees Retirement Systems Of Ohio holds 0% or 131,897 shares. Lincoln National Corp stated it has 0% of its portfolio in OPKO Health, Inc. (NASDAQ:OPK). D E Shaw And accumulated 0% or 64,790 shares. Qci Asset Mgmt Incorporated owns 790 shares. Jane Street Gp Ltd Liability Co reported 0.01% in OPKO Health, Inc. (NASDAQ:OPK). First Allied Advisory Incorporated invested 0% in OPKO Health, Inc. (NASDAQ:OPK).

Phillip Frost, CEO & Chairman of Opko Health Inc, in an insider buying deal bought some 153,000 shares whose amount is estimated to be $458,790 at average stock price of $3.0. It seems he is very active lately as in the last month, he silently bought additional 1.02 million shares of the company, worth $3.22 million USD. Because it was a big one investment, it’s not likely to stay unnoticed one. Phillip Frost currently owns 190.08 million shares or 33.97% of Opko Health Inc’s total market cap (Market Capitalization is a measurement of business value based on share price and number of shares outstanding).

The stock decreased 2.00% or $0.04 during the last trading session, reaching $1.96. About 600,899 shares traded. Infinity Pharmaceuticals, Inc. (INFI) has declined 38.35% since April 4, 2017 and is downtrending. It has underperformed by 49.90% the S&P500.

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. The company has market cap of $101.85 million. The Company’s lead product candidate includes IPI-549 an orally administered immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma is in Phase 1 clinical study. It currently has negative earnings. The firm has a license agreement with Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib, a selective inhibitor of the PI3K delta and gamma isoforms, including DUO study that is in randomized Phase III clinical study for patients with relapsed/refractory chronic lymphocytic leukemia and products containing duvelisib; Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; and Takeda Pharmaceutical Company Limited to develop and commercialize duvelisib.

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) Institutional Positions Chart